

**Official FAX Transmittal**

APR 14 2005

Docket No.: 39766-0160 R1C1

**Applic. No.:** 10/010,667  
**Confirm. No.:** 1346  
**Applicant:** Daniel AFAR  
**Filed:** December 6, 2001  
**For:** PEPTIDES DERIVED FROM STEAP1

**Group Art Unit.:** 1642  
**Examiner:** Gary B. NICKOL


---

**To:** USPTO Centralized FAX number **Fax:** 703.872.9306  
**From:** Daniel M. Becker (Reg. No. 38,376)  
**Telephone:** 650.324.7014  
**Direct Fax:** 650.324.6665  
**No. of Pages:** 3 (including cover)

---

**Submitted herewith for filing:**

- 1) Power of Attorney and Correspondence Address Indication Form (1 page).
- 2) Statement under 37 C.F.R. § 3.73(b) (1 page).



 Respectfully submitted,

Daniel M. Becker (Reg. No. 38,376)

**CERTIFICATE OF FACSIMILE TRANSMISSION--37 CFR §§ 1.6(d), 1.8(a)(1)(i)(B)**

I hereby certify that this correspondence is being transmitted by facsimile on April 14, 2005 to the United States Patent and Trademark Office at the facsimile number set forth above.

Date: April 14, 2005


 Daniel M. Becker

The information contained in this communication is intended only for the use of the addressee and may be confidential, may be attorney-client privileged and may constitute inside information. Unauthorized use, disclosure or copying is strictly prohibited, and may be unlawful. If you have received this communication in error or you have not received all pages, please call the sender immediately at (650) 324-7000.

Heller Ehrman White & McAuliffe LLP [www.hewm.com](http://www.hewm.com)
 San Francisco Silicon Valley Los Angeles San Diego Seattle Portland Anchorage New York Washington, D.C. Madison, WI  
 Hong Kong Beijing Singapore Affiliated Offices: Milan Paris Rome

APR 14 2005

PTO/SB/81 (11-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	10/010,667
Filing Date	December 6, 2001
First Named Inventor	Daniel E. AFAR
Title	PEPTIDES DERIVED FROM STEAP-1 (as amended)
Art Unit	1642
Examiner Name	Gary B. NICKOL
Attorney Docket Number	39766-0160 R1C1

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

 Practitioners associated with the Customer Number:

25213

OR

 Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

 The address associated with the above-mentioned Customer Number:

OR

 The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Fax		

I am the:

 Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**

Signature	<i>Steve Heller</i>	Date	13-Apr-05
Name	<i>Steve Heller</i>	Telephone	310.820.8029
Title and Company	S.E.U.R., C.S.O.		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

 \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/85 (09-04)

Approved for use through 07/31/2008, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Daniel E. AFAR et al.Application No./Patent No.: 10/010,687 Filed/Issue Date: December 6, 2001Entitled: NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOFAgensys, Inc. a CORPORATION

(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR  
B  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: all inventors To: Urogenesys, Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 010903, Frame 0988, or for which a copy thereof is attached.

2. From: Urogenesys, Inc. To: Agensys, Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 012193, Frame 0267, or for which a copy thereof is attached.

3. Which assignments run to the instant continuation application.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Aya Jakabovitz

Signature

Printed or Typed Name

Sr. U.P., C.S.O.

Title

13-April-05

Date

310.870.8029

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.